clofibrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
clofibrate derivatives, peroxisome proliferator activated receptor-alpha(PPAR-alpha) agonists	694	637-07-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clofibrate ticlobran xyduril p-chlorophenoxyisobutyric acid ethyl ester lipavil lipavlon lipomid liprinal miscleron misclerone	A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986) Molecular weight: 242.70 Formula: C12H15ClO3 CLOGP: 3.68 LIPINSKI: 0 HAC: 3 HDO: 0 TPSA: 35.53 ALOGS: -3.92 ROTB: 5 Status: OFM Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clofibrate
ticlobran
xyduril
p-chlorophenoxyisobutyric acid ethyl ester
lipavil
lipavlon
lipomid
liprinal
miscleron
misclerone

A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)

Molecular weight: 242.70
Formula: C12H15ClO3
CLOGP: 3.68
LIPINSKI: 0
HAC: 3
HDO: 0
TPSA: 35.53
ALOGS: -3.92
ROTB: 5

Status: OFM

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	2	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	11 %	Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
Feb. 8, 1967	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C10AB01	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN Fibrates
CHEBI has role	CHEBI:35679	antilipemic drugs
CHEBI has role	CHEBI:35821	anticholesteremic drugs
CHEBI has role	CHEBI:70782	PPAR-alpha agonist
CHEBI has role	CHEBI:176497	geroprotectors
MeSH PA	D000924	Anticholesteremic Agents
MeSH PA	D000963	Antimetabolites
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents
CHEBI has role	CHEBI:24527	herbicides
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:83399	marine xenobiotic metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hyperlipidemia	indication	55822004	DOID:1168
Partial Central Diabetes Insipidus	off-label use

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Peroxisome proliferator-activated receptor alpha	Nuclear hormone receptor	Q07869	PPARA_HUMAN	AGONIST	IC50	4.25		IUPHAR	CHEMBL
Fatty acid-binding protein, liver	Unclassified		FABPL_RAT		Kd	5.22		CHEMBL

External reference:

ID	Source
4018482	VUID
N0000146804	NUI
D00279	KEGG_DRUG
2594	RXNORM
4018482	VANDF
C0009002	UMLSCUI
CHEBI:3750	CHEBI
CHEBI:34648	CHEBI
CHEMBL565	ChEMBL_ID
DB00636	DRUGBANK_ID
D002994	MESH_DESCRIPTOR_UI
2796	PUBCHEM_CID
2667	IUPHAR_LIGAND_ID
1530	INN_ID
HPN91K7FU3	UNII
348	MMSL
4474	MMSL
d00196	MMSL
002056	NDDF
387439004	SNOMEDCT_US
77035009	SNOMEDCT_US
C0009003	UMLSCUI
2439	INN_ID
2797	PUBCHEM_CID
D002995	MESH_DESCRIPTOR_UI

Pharmaceutical products:

None